Last updated on March 2019

Non-interventional Post-authorisation Study to Document the Immunogenicity Safety and Efficacy of NUWIQ


Brief description of study

Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients) and routine clinical practice. Besides aspects such as general product safety and efficacy, there will be a focus on immunogenicity, particularly on inhibitor development. The diagnosis of FVIII inhibitor will be based on clinical observations and confirmed by FVIII inhibitor testing in the laboratory.

Clinical Study Identifier: NCT02962765

Contact Investigators or Research Sites near you

Start Over

Sigurd Knaub, PhD

Hopital Pontchaillou
Rennes, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.